WADA/Doping: Effects & Evidence—what is actually supported

WADA/doping is rarely discussed in terms of “effects” in practice—what matters is detection: whether prohibited substances (or their metabolites) can be reliably found analytically under WADA rules. That is why the evidence base is often analytic (detection, identification, detection windows), whereas clinical endpoints for performance or health are much less central.

Why “effects” in WADA doping are often secondary

At its core, WADA doping is about a question rather than a desired biological effect: Can a prohibited agent (or a relevant metabolite/marker) be detected in the sample? That is exactly why many studies are structured around concentrations, detectability, and identification criteria—not whether a substance improves performance or “is healthy.”

A second reason: many investigations that directly relate to WADA relevance are frequently methodological. This includes, for example, the use of high-resolution mass spectrometry to safely identify metabolites (e.g., in hormone/analog contexts such as GnRH and analogs in urine; (Uçaktürk et al., 2025, PMID 41138283)) or the validation of detection/identification strategies for intact testosterone-sulfate metabolite targets (Angelis et al., 2026, PMID 41834284). Such data are directly relevant to doping control, while performance assessment impact is indirect.

A third layer follows: even if you wanted to study clinical effects, key uncertainties would remain in doping cases (timing of intake, individual pharmacokinetics, matrix differences between urine and blood, training status). Your studies therefore mostly show: which substances can be detected reliably—and under what conditions detectability can be stronger. This is also the pattern visible in the CBD RCT (Gillham et al., 2026, PMID 40920736): here, the “effect” is less about a performance or health benefit and more about measurable urinary detectability after daily use, enhanced by physical activity.

Important: that does not mean effects are irrelevant. But in WADA cases, effects are practically rarely what drives decisions. If you’re considering a substance choice, the “effects” layer is hard to support without reliable detection and safety data.

Evidence hierarchy: RCTs, analytical studies, and reviews

If you want to weigh the evidence carefully, an evidence hierarchy is helpful: at the top are RCTs with a clear intervention; below are method-focused analytical studies; reviews synthesize cross-sectional data, but they cannot replace direct efficacy/safety RCTs.

Within your set, the strongest evidence for the concrete WADA-relevant point “detectability after use” is an RCT on daily cannabidiol: Gillham et al. (2026, PMID 40920736) studied daily use of a broad-spectrum cannabidiol preparation and found detectable concentrations of cannabinoids in urine after use that are captured by the WADA rules. This matters because the study does not only speculate “it could happen”—it shows measurable urine values under conditions that resemble real use. At the same time, the RCT provides primarily evidence for analytical detectability, not for a dose–response effect on performance or health.

Below that are methodological works showing how doping-control searches are performed for particular substance classes. For example, Uçaktürk et al. (2025, PMID 41138283) analyzed growth hormone–releasing hormone and analogs in urine using Nano-Liquid Chromatography coupled to Quadrupole/Orbitrap mass spectrometry. Such work improves what detection and identification can look like in real controls—not the therapeutic or performance-related efficacy.

For risks stemming from supplement contamination, the evidence comes from reviews that cannot play the same role as an “effects” RCT. Al-Saad et al. (2026, PMID 41908212) is a systematic review on undeclared prohibited substances and pharmacological adulterants in sport supplements (prevalence, detection, risks). And Puscasiu et al. (2025, PMID 41097223) discusses adulteration involving anabolic steroids and frames the risk from “subtly present” to “fraudulent.” These are not performance-endpoint studies—but they address the main practical mechanism behind many “WADA risks”: supplement adulteration.

What this hierarchy means for you: for WADA/detection, RCTs are rare, but analytical studies and reviews provide the “hard” foundation. By contrast, an effect expectation without detection and adulteration data is not robust.

What the evidence specifically provides for WADA relevance of CBD

The RCT by Gillham et al. (2026, PMID 40920736) provides the clearest evidence in your set that daily cannabidiol can generate measurable concentrations of cannabinoids in urine that are captured by WADA analytics. This is crucial because it is not only a theoretical possibility—it is about observed urine detectability after use.

Even more relevant for interpretation: the study also indicates that physical activity may enhance urine detectability. Thus, a central practical point is supported: the training/exertion status is not merely “context”—it can affect how clearly urinary markers can be detected. For WADA, this is relevant because testing is intended to reflect realistic sporting conditions.

What the RCT does not automatically provide: a clearly transferable statement that “CBD at dose X improves performance/health,” or a safe dose–response curve for health or performance outcomes. In WADA contexts, the framing is often analytic: it is about whether and how reliably a marker becomes detectable. The study answers that analytic/detection question—but it should not be read as permission for “performance or health optimization without risk.”

If you translate this into a risk logic, the core message is sober: Daily broad-spectrum CBD can produce WADA-relevant urine markers, and sport can increase detectability (Gillham et al., 2026, PMID 40920736). That does not automatically make CBD broadly “dangerous” in a general medical sense—but it changes relevance: for competitions and anti-doping controls, less emphasis is placed on subjective effects and more on urine detectability.

If you want to look at a lifestyle lever that is often underestimated in practice, continue to the section below on supplement avoidance and quality assurance.

Lifestyle levers before supplements: how to reduce doping risks

If your goal is to “avoid competitive doping,” the most effective lever in the real world is usually not a single “safe supplement,” but minimizing sources that are not verifiable. The reason is fairly clear from the available data: the most common real-world mechanism behind WADA risk is supplement contamination with undeclared pharmacologically active ingredients (“adulteration”).

Reviews target exactly this point. Al-Saad et al. (2026, PMID 41908212) systematically summarizes how often undeclared prohibited substances and pharmacological adulterants appear in sport supplements, how they are detected, and what risks this creates for athletes. Puscasiu et al. (2025, PMID 41097223) categorizes adulteration involving anabolic steroids and describes the spectrum from seemingly “innocent” products to behavior that is effectively fraudulent. This gives you a decision basis: even if a product sounds “trustworthy,” the actual active ingredient composition may differ.

In addition, CBD illustrates that even with deliberate intake, “what is on the label” is not necessarily what is relevant for WADA. The CBD RCT shows that daily use can generate detectable urine markers and that sport can strengthen this detectability (Gillham et al., 2026, PMID 40920736). Lifestyle thus becomes directly relevant too: training status can matter in terms of detectability.

Practically, prioritize:

• Sleep, movement, nutrition are your most important performance and health levers—they are not a “WADA-analytics black box.”
• If you still use supplements: what matters is quality assurance that goes beyond marketing. (In your data set, the adulteration aspect is supported most; specific manufacturer seals are not assessed in detail as evidence of effectiveness.)
• “More” is not automatically “better.” Ultimately, what counts for WADA is what ends up in the sample.

If you want, you can structure your supplement decisions along other lifestyle levers as well—for example, by using protein-related timing questions (see Protein Timing: Effects & Evidence—what is supported) or by considering workload and stress parameters (see Training Stress: Effects & Evidence—what is supported).

Analytics & detection: hormones, metabolites, and emerging detection routes

For WADA, “detection” is more than a simple yes/no. It is about analytical quality: identification (is it truly the correct substance/metabolite?), sensitivity (can it be seen at low concentrations?), and interpretability (how is exposure demonstrated within the doping control context?). Several studies in your set reflect these points.

One example is Uçaktürk et al. (2025, PMID 41138283). The study analyzed GnRH (Gonadotropin-Releasing Hormone) and its analogs in urine using Nano-LC coupled with Quadrupol/Orbitrap mass spectrometry. The methodological focus shows: for peptide/hormone-like substances, you need high-resolution, specification-sensitive methods to reliably identify markers in complex urine matrices. This type of work matters for the real-world doping context because new or hard-to-recognize compounds might otherwise remain “under the radar.”

Even with classical steroids, the metabolite layer is central. Angelis et al. (2026, PMID 41834284) evaluated different detection and identification methods for intact THM testosterone-sulfate metabolite targets in the doping control setting. This is relevant because WADA does not only look for “original molecules,” but also for metabolites that can reflect exposure over time.

Finally, “emerging therapeutics” is a recurring theme. Thevis et al. (2014, PMID 24906629; and PMID 25382550) discuss analytical approaches for detecting newly emerging therapeutic substances and the status and future outlook for detection of peptide doping agents. Such reviews make it clear that the detection landscape is dynamic: new substance classes and analogs are developed, and laboratories must update strategies accordingly.

Another concrete analytical layer is addressed by Di Giorgi et al. (2026, PMID 40668262): In vitro, the study shows how metabolites can be identified to document exposure (here specifically in the context of chlorthalidone). This is an example of how doping control considers “biology + analytics” together: which metabolites arise in the body, and how exposure can be supported.

Important: these studies primarily support how detection is performed. They do not automatically provide health or performance effects—however, they explain why WADA controls increasingly can cover more complex substance categories.

Evidence snapshot: what is supported and what the data refer to

In practice, it is helpful to separate the evidence into three categories: (1) direct detectability after use (strongest), (2) analytical detection and identification studies, and (3) supplement adulteration as a risk source. The following overview groups exactly these points from the available sources in your set.

Key takeaway from this “evidence map”: for WADA, the strongest robust evidence exists where you can measure detectability after controlled use. For other substance classes, the data are often method-focused and/or synthesized via reviews. This is not a research weakness—it reflects what doping control needs operationally.

Supplement reality: contamination and “adulteration” are supported

If you want to take away just one risk assumption, take this: in sport supplements, contamination is demonstrably a relevant problem. The studies in your set do not support this claim only through “single-case anecdotes,” but through reviews that systematically address detection and risks.

Al-Saad et al. (2026, PMID 41908212) is a systematic review of undeclared prohibited substances and pharmacological adulterants in sport supplements—including information on prevalence, detection (i.e., which analytical strategies allow adulterants to be detected reliably), and risks in sport. This matters because it removes the evidence from an “anecdotal feeling”: it describes a recurring pattern where prohibited substances can appear in products without being declared.

Puscasiu et al. (2025, PMID 41097223) adds a practical framing to this: adulteration can be designed so that a product seems “harmless” to athletes, yet still contains anabolic steroids. The study addresses the real dilemma: even if you are not trying to cheat, consumption can still place you in a range that doping controls interpret as exposure.

This supplement layer also explains why “effects” alone may not be a protective signal. If a product is genuinely contaminated, the subjective effects you observe are not a reliable safety indicator. For WADA, what matters is the analytical reality in the body—and that depends on what is inside the supplement and how the body processes it.

Complementary analytical approaches can help document exposure despite complex metabolic pathways. As shown by Di Giorgi et al. (2026, PMID 40668262), in vitro metabolite identification can be used to document exposure in doping contexts. And at a broader level, reviews such as those by Thevis et al. (2014, PMID 24906629; PMID 25382550) clarify that detection involves both newly emergent therapeutic substances and peptide agents, and that methods continue to evolve.

Important for interpretation: the data support the risk and the detectability—but they do not automatically provide a “which product is safe” instruction. To do that would require additional quality data for specific manufacturers and their testing programs, which are not included in your set.

What you should take from this

• In WADA/doping, the key question is usually not what effects the substance has, but whether and how safely prohibited substances or metabolites are detectable in urine.
• The strongest direct evidence in your set is Gillham et al. (2026, PMID 40920736): daily broad-spectrum cannabidiol can produce WADA-relevant cannabinoid concentrations in urine; physical activity can strengthen detectability.
• For many other substance categories, the data are primarily analytical studies and reviews: they show how detection/identification works, not the primary performance or health effects.
• The biggest practical risk for competitive athletes, according to the reviews, is supplement adulteration (Al-Saad et al., 2026, PMID 41908212; Puscasiu et al., 2025, PMID 41097223)—so lifestyle levers and cautious supplement strategies are especially central in the competition context.